Hemab Therapeutics Holdings (COAG) stock

Blood therapies , market cap $2.1B

Therapies for blood coagulation disorders

Worth $2.1B

$38.77

-9.44%

As of Tuesday's close · Live for Pro members at the open

Why is COAG down?

Down 21% from Nov 6 to Nov 10.

Hemab Therapeutics fell 21% from Nov 6 to Nov 10. 13 points of it came on Nov 9.

Sources: Price history, Nov 10, 2026

Tell me next time COAG moves

Free account, no card. An optional alert when COAG moves or its score changes.

Or see it live, free until Thursday morning. No account.

1 more reason, free with an account →The timeline and its peers, for Pro members.

Quality Score

Below Average

In its industry

#116of 281

Biotech

Checks firing

2of 14

Trending up

From its high

-30.0%

under its best since listing

COAG's Quality Score fell 4 points on Tue, Nov 10, to 1. Its price fell below its average of the last 21 days (2 chart checks stopped).

New listing, trading since May 1, 2026. 134 trading days so far, so 2 of the 14 chart checks wait for more history.

Follow COAG's trial news. Pro members can get an alert when Hemab Therapeutics Holdings files news, and see its trials, share raises, and its CEO's filings.

Get an alert when COAG files news on its trialsSee it live, free until Thursday morning. No account. No card. Then keep going with a free account.

We do the work for you. Every stock is scored and ranked, every 15 seconds while the market is open. Here it's 15 minutes behind. Pro members see it live.

Next2H 2026“…data package as sufficient to proceed to a Phase 3 pivotal trial in GT; Phase 3 initiation planned 2H 2026”Trial start · SEC filing · Aug 11

Key facts on COAG

Key facts on COAG
Holding it back	Moves 8.8% a day with no profit behind it
Latest filing	8-K, Nov 10 Reported its quarterly results

1 more reason behind COAG's 1, free with an account →

COAG in the news

ReportThis morning: a loss of $0.58 a share. Past reports ›

In the newsCOAG: Hemab Therapeutics Holdings Inc. filed SEC Form 8-K: Results... quantisnow.com and 3 more · 7:11 AM ET

What's next

Sat Dec 12: American Society of Hematology…Industry event · date confirmed.

Expected to report Thu Feb 4, before the open

After its last 3 reports it closed -2.1% on average, higher 1 of 3 times.

1 more date ahead: the IPO anniversary, for Pro members.

COAG catalysts

Coming up

What's next for COAG, and how long its cash lasts

Next step the company has named

2H 2026“sutacimig clinical data package as sufficient to proceed to a Phase 3 pivotal trial in GT; Phase 3 initiation planned 2H 2026”Trial start · SEC filing · Aug 11

What it means: when a trial begins, or reaches the stage the company named.

A trial underway: HMB-002 in Participants With Von Willebrand DiseasePhase 1/2 · Recruiting · 108 people · main data estimated Jul 2027 · NCT06754852

3 more trials, 1 more milestone and 6 filings, for Pro members.

Cash runway Jun 30 balance sheet

$457M in cash

Fewer than four quarters of cash flow are on file.

What it means: a runway is counted only when each of the last four quarters used cash. The company's estimate is “into 2029” (8-K, Nov 10).

For Pro members: the cash used each quarter, and the math.

Dilution on the horizon

No shelf registration or at-the-market program on file in the last three years.

For Pro members: 1 raise and its amount, and the share count against a year ago.

Insiders

Director RA CAPITAL MANAGEMENT, L.P. bought 2,840,429 shares on May 6.

From Form 4: open-market buys and sales only.

For Pro members: every trade.

Get an alert when COAG files news on its trialsA free account. No card.

See every upcoming FDA date →

FDA dates in the next 60 days

Decision dates and advisory committee meetings the companies have announced in their filings, soonest first and small companies first.

DateStockDrug

In 12 daysFDA decisionIn 12 days · FDA decisionCAPRCapricor TherapeuticsDeramiocelCAPRCapricor Therapeutics · $500MDeramiocelFDA decision due (PDUFA)
In 12 daysFDA decisionIn 12 days · FDA decisionSVRASavaraMolgramostimSVRASavara · $900MMolgramostimFDA decision due (PDUFA)
In 42 daysFDA decisionIn 42 days · FDA decisionMLYSMineralys TherapeuticsLorundrostatMLYSMineralys Therapeutics · $1.3BLorundrostatFDA decision due (PDUFA)

14 more FDA dates and 103 trial data dates in the next 60 days, each on the FDA calendar. Pro members see whether each company's cash lasts past its date, with an optional alert before it. See all 151 dates, ranked →

Why COAG scores 1

Below Averagefor quality, not price, 2 of 14 chart checks firingWhat the Quality Score means

+2Chart checks 2 of 14 firing right now, one point each
−2Volatility moves 8.8% a day with no profit or positive free cash flow over four quarters on fileA daily range of 5% or more with nothing behind it (no profit or cash flow, sales shrinking, or 10% more shares outstanding with no free cash flow): -1, or -2 from 8%.

Run-up adds

No effect today: Long-term trend, Size, Profit, Growth, Dilution, Cash flow, Persistence, and News.

What every line is worth, and the reason behind it, on COAG and every other stock.Get in free →

Price, score, chart checks, and the industry rank are from a snapshot taken at 11:18 PM ET, at least 15 minutes behind. How we rank stocks.

Tested. Our top-scored stocks returned 2.2x the average stock over the next month. Reconstructed after the fact; recorded live since Sep 9, 2026. How we tested it

How COAG ranks in Biotech

COAG is #116 of 281 by Quality Score.

How COAG ranks in Biotech
Rank	Stock	Checks	Quality Score
1	ONCBeOne Medicines	8/14	24
2	VCELVericel	8/14	22
3	ETONEton Pharmaceutcials	9/14	20
	CLDXCelldex Therapeutics		Open for its score
	CLYMClimb Bio		Open for its score
	COGTCogent Biosciences		Open for its score
	COLLCollegium Pharmaceutical		Open for its score
116	COAGHemab Therapeutics	2/14	1

Cash and short-term investments: COAG $457M, HALO $1.07B, CGON $984M, NBIX $738M.

When does COAG report earnings, and what happens after?

Expected to report Thu Feb 4, before the open (in 86 days).

What an earnings report is: every 3 months, a company tells everyone how much it sold and earned. We read the figures, the outlook, and how the stock moved after.

What COAG reported on Nov 10, 2026

The quarter

A loss of $0.58 a share, from $18.04.

“The decrease in net loss per share primarily reflects the increase in weighted-average shares outstanding during the three months ended September 30, 2026 following the Company’s initial public offering and the subsequent conversion of preferred stock into common stock in May 2026 in connection with the closing of the Company’s initial”

The quarter that ended Sep 30, from the company's press release

The press release The filing on EDGAR

Where the sales came from

COAG's results filing gives no sales by line in a table we read.

The outlook

No outlook figures read from this release.

In the company's words

“The increase was due to costs related to the advancement of clinical programs , increases in personnel-related expenses and equity-based compensation, in addition to discovery and consulting fees related to company growth to support the advancement of our programs.”

From its results filing (SEC filing · Nov 10)

2 more sentences, for Pro members.

The numbers

Market value: $2.1B; today

No analyst estimates on Breakaway: every figure here is filed.

The whole report on COAG: every line of its sales, every outlook beside the one it replaced, and the company's words, for Pro members.

Close after the report, last 3

-0.6%+3.8%-9.4%

May 21Aug 11Nov 10

Reported	When	Gap	Reaction	5 days
Nov 10, 2026Before open	Before open	-6.3%	-9.4%	not yet
Aug 11, 2026Before open	Before open	0.0%	+3.8%	+7.5%
May 21, 2026Before open	Before open	-1.5%	-0.6%	+5.8%

COAG closed higher after 1 of its last 3 reports.

COAG has 2 of 14 chart checks firing

Trend1 of 5 shown

MA FAN 21 EMA W.EMA HH/HL 52W HI

Volume1 of 3 shown

VOL VDU U/D VOL

Tight range1 of 3 shown

ATR SQZ SQUEEZE NR7

Buying1 of 3 shown

OBV+CLOSE HI SPRING

The other 10 checks on COAG, and all 14 on every stock.Get in free →

COAG RSI today: 49.6, above its 50-day average

Not scored

RSI 49.6, MACD above signal. Not scored.13 readings

The deep dive on COAG

What it does and how it makes money1 findingFor Pro members1 finding on what COAG does and how it makes money, for Pro members
Where it stands2 findings1 offering of shares or notes since May 2026, $302M in all.SEC filing · May 1, 2026
Who holds and trades it2 findingsFor Pro members2 findings on who holds and trades COAG, for Pro members
Against its closest peers4 peersCash and short-term investments: COAG $457M, HALO $1.07B, CGON $984M, NBIX $738M.

4 more findings on COAG, each with its source, for Pro members.

COAG share count over time

Shares: 31.8 times the count a year ago (to Jun 30).

Shares of COAG outstanding, as filed
Shares outstanding	As of
46.7M	Jul 31, 2026
46.7M	May 8, 2026

Offerings, shelves, and splits of COAG, from its filings
From its filings	Filed
Raised $301.5M in a sale of shares, about 14% of its market value	May 1, 2026
Registered shares for sale (S-1)	Apr 10, 2026

COAG insider trades

2 insiders bought $1.8M across 4 filings in the last 6 months. No open-⁠market sales on record. The newest:

BuyRa Capital Management, L.P.$1.5M10% ownerat $24.98 on Jun 16, filed Jun 17

BuyRa Capital Management, L.P.10% owner$1.5Mat $24.98 on Jun 16, filed Jun 17

All 4 insider filings on COAG from the last six months, for Pro members.

All COAG insider trades

COAG's officers and directors

Officers and directors with a Form 4 in the last 12 months.

John MaraganoreDirector · no trades on file

See insider trades by person

Which ETFs hold COAG?

In ETFs: COAG is under 0.1% of VTI, the most of the 24 funds Breakaway covers, by their holdings as filed for Jun 30, 2026.

About Hemab Therapeutics Holdings

Hemab Therapeutics Holdings Inc is a clinical-stage biotechnology company developing therapies for the treatment of blood coagulation disorders. It focuses on discovering, developing, and commercializing treatments for conditions such as Glanzmann thrombasthenia, Factor VII deficiency, and von Willebrand disease. Its flagship candidate, sutacimig (HMB-001), is a bispecific antibody currently in clinical trials for the prophylactic treatment of Glanzmann thrombasthenia and Factor VII deficiency. The company has one operating segment, engaged in the research and development of prophylactic therapeutics for bleeding disorders.

Cambridge, MAhemab.com

Listed on Nasdaq on May 1, 2026, and is 115% above its $18 offer price now. Its IPO filing and first days

Here is what Pro members see.

The same page for Pro members, on Microsoft
Its Quality Score and rank, the line that drives it, and the live price.
The full chart
A year of candles to start, out to the whole history, with insider trades marked and the Quality Score under the price.
Every line of the score
Price action, the company, and signals, each with its points, on COAG and every other stock.
FDA dates, counted down
Each date in the company's words, its cash against the date, and an optional alert before it.
CEOs buying their own stock
Every CEO buy, biggest names first. Sort, filter, save the list, and set optional alerts.
Congress trades
A member's trades, newest first, each with its amount. Sort and filter the whole list.
14 chart checks, read for you
The ones firing on the stock, each in plain words, its rule a tap away.
Earnings, week by week
Who reports each day, and how each stock took its last four reports.
The market map
Every stock a box, colored by its Quality Score.
Themes, ranked live
Each theme's stocks ranked by Quality Score, live. Here, AI chips.
The top 10, every day
The ten highest Quality Scores at each close, kept day by day, week by week.
Optional alerts, your way
Pick a stock, a score, a price, a filing, or a whole scan. It tells you by push or email.
Your watchlist, scored
Your stocks by Quality Score, today's move, or name.
On your phone and your laptop
The same account and watchlist on both, each laid out for its screen.

Prices refresh every 2.5 seconds during market hours.
Optional alerts by push, email, or the bell.
Add it to your Home Screen and it opens like an app.

Pro members see every line of every stock's score.

What would turn COAG's score around: 4 things
4 more filings explained, a plain line each
Real-⁠time prices, no delay

BreakawayJun 17Ra Capital Management, L.P. bought COAG$1.5M at $24.98, filed Jun 17

Alerts are optional.

See COAG's 14 chart checks

See it live, free until Thursday morning. No account. No card. Then keep going with a free account.

Straight AnswersStraight Answers

As of Nov 10, 2026: COAG's Quality Score is 1 (Below Average), #116 of 281 in Biotech. Insiders bought $1.8M in the last 6 months (Form 4).

What does COAG's Quality Score say?

COAG scores 1 today, which Breakaway calls Below Average. It is #116 of 281 in Biotech by Quality Score, with 2 of 14 chart checks firing. Down 21% from Nov 6 to Nov 10. Shares: 31.8 times the count a year ago (to Jun 30). Breakaway does not say whether to buy any stock: the score does not know your situation, and it is not a recommendation to buy or sell anything. Please do your own research.

What is COAG's Quality Score?

COAG scores 1 today, which Breakaway calls Below Average (0 to 5). That is #116 of 281 in Biotech by Quality Score. The score adds up the chart checks, the trend, the company's filed sales, its profits, the news, insider trades, and Congress trades. The section above lists the lines behind COAG's 1.

Are insiders buying COAG?

2 insiders bought $1.8M across 4 filings in the last 6 months. No open-⁠market sales on record. The newest is Ra Capital Management, L.P., 10% owner, who bought $1.5M on Jun 16. Every filing, with the scored weight, for Pro members.

Are the prices delayed?

Only on the public pages, which run at least 15 minutes behind. Pro members, and anyone on a guest pass, see real-time prices: the scanner refreshes every 15 seconds, and your watchlist every few seconds, pre-market and after hours included.